10.1007/s40097-021-00398-6

Effect of thymoquinone-loaded lipid–polymer nanoparticles as an oral delivery system on anticancer efficiency of doxorubicin

XML
  • Faezeh Abbaspour Moghaddam1,
  • Mahboubeh Ebrahimian1,
  • Fatemeh Oroojalian2,
  • Rezvan Yazdian-Robati3,
  • Fatemeh Kalalinia4,
  • Lobat Tayebi5,
  • Maryam Hashemi*6,
  1. School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, IR
  2. Department of Advanced Sciences and Technologies, School of Medicine, North Khorasan University of Medical Sciences, Bojnurd, IR Natural Products and Medicinal Plants Research Center, North Khorasan University of Medical Sciences, Bojnurd, IR
  3. Molecular and Cell Biology Research Center, Faculty of Medicine, Mazandaran University of Medical Sciences, Sari, IR
  4. Department of Pharmaceutical Biotechnology, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, IR
  5. Marquette University School of Dentistry, Milwaukee, WI, 53233, US
  6. Department of Pharmaceutical Biotechnology, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, IR Nanotechnology Research Center, Pharmaceutical Technology Institute, Mashhad University of Medical Sciences, Mashhad, IR

Published in Issue 09-04-2021

How to Cite

Moghaddam, F. A., Ebrahimian, M., Oroojalian, F., Yazdian-Robati, R., Kalalinia, F., Tayebi, L., & Hashemi, M. (2021). Effect of thymoquinone-loaded lipid–polymer nanoparticles as an oral delivery system on anticancer efficiency of doxorubicin. Journal of Nanostructure in Chemistry, 12(1 (February 2022). https://doi.org/10.1007/s40097-021-00398-6
Crossref
Scopus
Google Scholar
Europe PMC

Abstract

Abstract In this study, thymoquinone (TQ) was encapsulated into lipid–polymer nanoparticles (LPNPs) consisting of phosphatidylcholine (PC) and poly lactide–co-glycolide (PLGA) to enhance anticancer and oral delivery efficiency of TQ. We also co-delivered TQ nanoparticles with free doxorubicin (DOX) to increase DOX efficiency. Single emulsion solvent evaporation method was exploited to prepare PLGA-TQ and PLGA-PC-TQ NPs. The physicochemical properties of synthetized NPs and their cellular uptake across Caco-2 cells were assessed. Cytotoxicity of different formulations of TQ and their co-delivery with free DOX were determined by MTT assay on colon cancer cell lines (C26). Cell migration was also evaluated by wound healing migration assay. LPNPs containing TQ with an average diameter of 184 nm and 60% loading efficiency showed more release at simulated intestinal fluid pH of 6.8 compared to polymeric NPs. At an acidic pH, however, the release of TQ from PLGA-PC was about 2% after 120 h. The cytotoxicity studies indicated that PLGA-PC-TQ NPs improved anticancer activity of DOX more than TQ NPs. Uptake of PLGA-PC-TQ through the Caco-2 cells was 2.5 times greater compared to NPs without PC. PLGA-PC-TQ NPs also exhibited significantly greater reduction of cancer cell migration. The results demonstrate that co-delivery of PLGA-PC encapsulated TQ through oral administration and free DOX could improve anticancer efficiency of DOX.

Keywords

  • Thymoquinone,
  • Doxorubicin,
  • Oral delivery,
  • PLGA,
  • Phosphatidylcholine

References

  1. Ma et al. (2017) Co-assembly of doxorubicin and curcumin targeted micelles for synergistic delivery and improving anti-tumor efficacy (pp. 209-223) https://doi.org/10.1016/j.ejpb.2016.11.033
  2. Wu H, L.S., Gong J, et al: VCPA, a novel synthetic derivative of α-tocopheryl succinate, sensitizes human gastric cancer to doxorubicin-induced apoptosis via ROS-dependent mitochondrial dysfunction. Cancer Lett.
  3. 393
  4. , 22–32 (2017).
  5. Kaur and M. (2012) Doxorubicin: a critical review on toxicity 5(5) (pp. 2890-2894)
  6. Oroojalian et al. (2018) Encapsulation of thermo-responsive gel in pH-sensitive polymersomes as dual-responsive smart carriers for controlled release of doxorubicin (pp. 45-61) https://doi.org/10.1016/j.jconrel.2018.08.039
  7. Chen and H., Dai, Z., Liu, Z, (2015) Nanoscale theranostics for physical stimulus-responsive cancer therapies (pp. 214-230) https://doi.org/10.1016/j.biomaterials.2015.09.018
  8. Jardim, G.L., D.; Valença, W.; Lima, D.; Cavalcanti, B.; Pessoa, C.; Rafique, J.; Braga, A.; Jacob, C.; da Silva Júnior, E.; et al: Synthesis of Selenium-Quinone Hybrid Compounds with Potential Antitumor Activity via Rh-Catalyzed C-H Bond Activation and Click Reactions. Molecules. 23(1), 83 (2017)
  9. Fang et al. (2018) Quercetin and doxorubicin co-delivery using mesoporous silica nanoparticles enhance the efficacy of gastric carcinoma chemotherapy (pp. 5113-5126) https://doi.org/10.2147/IJN.S170862
  10. Langroodi et al. (2016) Evaluation of the effect of crocetin on antitumor activity of doxorubicin encapsulated in PLGA nanoparticles (pp. 23-34)
  11. Pishavar et al. (2019) Cholesterol-conjugated PEGylated PAMAM as an efficient nanocarrier for plasmid encoding interleukin-12 immunogene delivery towards colon cancer cells 36(3)
  12. Ghazanfary et al. (2019) Density functional theory study of antioxidant adsorption onto single-wall boron nitride nanotubes: design of new antioxidant delivery systems 22(7) (pp. 470-482) https://doi.org/10.2174/1386207322666190930113200
  13. Rashidi et al. (2013) Electromechanical properties of vertically aligned carbon nanotube (pp. 332-336)
  14. M, A.: Thymoquinone in the clinical treatment of cancer: Fact or fiction? Phcog. Rev.
  15. 7
  16. , 117–120 (2013).
  17. Woo CC, K.A., Sethi G, Tan K: Thymoquinone: potential cure for inflammatory disorders and cancer. Biochem. Pharmacol.
  18. 38
  19. , 443–451 (2012).
  20. Banerjee S., P.S., Azmi A., Wang Z., Philip P., Kucuk O: Review on molecular and therapeutic potential of thymoquinone in cancer. Nutr. Cancer.
  21. 62
  22. , 938–946 (2010).
  23. Bhattacharya S., A.M., Patra P., Mukherjee S., Ghosh S., Mazumdar M., Chattopadhyay S., Das T.,, Chattopadhyay D., A.A.: PEGylated- thymoquinone-nanoparticle mediated retardation of breast cancer cell migration by deregulation of cytoskeletal actin polymerization through miR-34a. Biomaterials.
  24. 51
  25. , 91–107 (2015).
  26. Badary OA, A.-S.O., Nagi MN, Al-Rikabi AC, Elmazar M: Inhibition of benzo(a)pyreneinduced forestomach carcinogenesis in mice by thymoquinone. Eur. J. Cancer. Prev.
  27. 8
  28. , 435–440 (1999).
  29. Kommineni N, S.R., Bulbake U, Khan W.: Cabazitaxel and thymoquinone co-loaded lipospheres as a synergistic combination for breast cancer. Chem. Phys. Lipids. 224, 104707(2019)
  30. Fatfat et al. (2019) Thymoquinone enhances the anticancer activity of doxorubicin against adult T-cell leukemia in vitro and in vivo through ROS-dependent mechanisms https://doi.org/10.1016/j.lfs.2019.116628
  31. Effenberger-Neidnicht K, S.R.: Combinatorial effects of thymoquinone on the anti-cancer activity of doxorubicin. Cancer Chemother. Pharmacol.
  32. 67
  33. (4), 867–874 (2011).
  34. Badary O., A.-S.O., Nagi M., Al-Bekairi A: Acute and subchronic toxicity of thymoquinone in mice. Drug Dev. Res.
  35. 44
  36. , 56-61 (1998)
  37. Dhadde, S.B., Patil, J.S., Chandakavathe, B.N., Thippeswamy, B., Kavatekar, M.G.: Relevance of Nanotechnology in Solving Oral Drug Delivery Challenges: A Perspective Review. Crit Rev Ther.
  38. 37
  39. (5) (2020).
  40. Jana et al. (2020) Biodegradable polymers in drug delivery and oral vaccination https://doi.org/10.1016/j.eurpolymj.2020.110155
  41. Liang, H., Friedman, J. M.,&Nacharaju, P: Fabrication of biodegradable PEG–PLA nanospheres for solubility, stabilization, and delivery of curcumin. Artif. Cells. Nanomed. Biotechnol.
  42. 45
  43. , 297–304 (2017).
  44. N. Csaba, M.G.-F.a.J.A., Adv: Nanoparticles for nasal vaccination. Drug. Deliv. Rev. 61(2), 140–157(2009).
  45. Ghitman, J., Biru, E.I., Stan, R., Iovu, H.: Review of hybrid PLGA nanoparticles: Future of smart drug delivery and theranostics medicine. Mater. Des.108805 (2020).
  46. Hashemi, M., Shamshiri, A., Saeedi, M., Tayebi, L., Yazdian-Robati, R.: Aptamer-conjugated PLGA nanoparticles for delivery and imaging of cancer therapeutic drugs. Arch. Biochem. Biophys. 108485 (2020).
  47. Jose et al. (2018) Polymeric lipid hybrid nanoparticles: properties and therapeutic applications 35(6) (pp. 555-588) https://doi.org/10.1615/CritRevTherDrugCarrierSyst.2018024751
  48. Mukherjee et al. (2019) Lipid–polymer hybrid nanoparticles as a next-generation drug delivery platform: state of the art, emerging technologies, and perspectives https://doi.org/10.2147/IJN.S198353
  49. Yu F, A.M., Zheng X, Li N, Xia J, Li Y, Li D, Hou Zh, Qi Zh, and Chen X D: PEG–lipid–PLGA hybrid nanoparticles loaded with berberine–phospholipid complex to facilitate the oral delivery efficiency. Drug Deliv. 24(1), 258–833 (2017).
  50. Ghahestani, Z., Langroodi, F., Mokhtarzadeh, A., Ramezani, M., Hashemi, M.: Evaluation of anti-cancer activity of PLGA nanoparticles containing crocetin. Artif. Cells. Nanomed. Biotechnol.
  51. 45
  52. (2016).
  53. Ahmad, R., Kaus, N.H.M., Hamid, S.: Synthesis and characterization of PLGA-PEG thymoquinone nanoparticles and its cytotoxicity effects in tamoxifen-resistant breast cancer cells. In Cancer Biology and Advances in Treatment. 65–82 (2020).
  54. Mona and Mottaleb (2016) Biodegradable thymoquinone nanoparticles for higher therapeutic efficiency in murine colorectal cancer (pp. 436-450)
  55. Oroojalian et al. (2019) Synthesis and evaluation of injectable thermosensitive penta-block copolymer hydrogel (PNIPAAm-PCL-PEG-PCL-PNIPAAm) and star-shaped poly (CL─ CO─ LA)-b-PEG for wound healing applications 20(10) (pp. 17194-17207) https://doi.org/10.1002/jcb.28980
  56. Zhao et al. (2005) Evaluation of combination chemotherapy: integration of nonlinear regression, curve shift, isobologram, and combination index analyses (pp. 7994-8004) https://doi.org/10.1158/1078-0432.CCR-04-1087
  57. Karimisani et al. (2015) Solamargine inhibits migration and invasion of human hepatocellular carcinoma cells through down-regulation of matrix metalloproteinases 2 and 9 expression and activity 29(5) (pp. 893-900) https://doi.org/10.1016/j.tiv.2015.03.012
  58. Alibolandi, M., Alabdollah, F., Sadeghi, F., Mohammadi, M., Abnous, K., Ramezani, M., Hadizadeh, F. (2016) Dextran-b-poly (Lactide-co-Glycolide) polymersome for oral delivery of insulin: in vitro and in vivo evaluation. JCR.
  59. 227
  60. .
  61. Nkabinde, L., Shoba-Zikhali, L., Semete-Makokotlela, B., Kalombo, M., Swai, H., Hayeshi, R., Naicker, B., Hillie, K., Hamman, J.: Permeation of PLGA Nanoparticles Across Different in vitro Models. Curr. Drug Deliv.
  62. 9
  63. (2012).
  64. Ana Rute Neves , S.M., Marcela A. Segundo and Salette Reis Nanoscale Delivery of Resveratrol towards Enhancement of Supplements and Nutraceuticals. Nutrients.
  65. 8
  66. (3), 131 (2015).
  67. Yu et al. (2017) PEG–lipid–PLGA hybrid nanoparticles loaded with berberine–phospholipid complex to facilitate the oral delivery efficiency 24(1) (pp. 825-833) https://doi.org/10.1080/10717544.2017.1321062
  68. Araste et al. (2020) Na+/K+ ATPase-targeted delivery to metastatic breast cancer models https://doi.org/10.1016/j.ejps.2019.105207
  69. Odeh F., I.S., Abu-Dahab R., Mahmoud I., Al Bawab A: Thymoquinone in liposomes: a studyn of loading efficiency and biological activity towards breast cancer. Drug Deliv.
  70. 19
  71. (8), 371–377 (2012).
  72. Mahmoud and Abdelrazek (2019) Cancer: Thymoquinone antioxidant/pro-oxidant effect as potential anticancer remedy https://doi.org/10.1016/j.biopha.2019.108783
  73. Imran et al. (2018) Thymoquinone: a novel strategy to combat cancer: a review (pp. 390-402) https://doi.org/10.1016/j.biopha.2018.06.159
  74. Schneider-Stock R., F.I., Zaki A., El-Baba C., Gali-Muhtasib H: Thymoquinone: fifty years of success in the battle against cancer models. Drug. Discov. Today.
  75. 19
  76. , 18–30 (2014).
  77. Bose et al. (2016) Lipid-based surface engineering of PLGA nanoparticles for drug and gene delivery applications https://doi.org/10.1186/s40824-016-0081-3
  78. Park JH, L.S., Kim JH, Kyeongsoon Park K: Polymeric nanomedicine for cancer therapy. Prog. Polym. Sci.
  79. 33
  80. , 113-137 (2008)
  81. He et al. (2012) Size-dependent absorption mechanism of polymeric nanoparticles for oral delivery of protein drugs 33(33) (pp. 8569-8578) https://doi.org/10.1016/j.biomaterials.2012.07.063
  82. Öztürk et al. (2019) Dexketoprofen trometamol-loaded poly-lactic-co-glycolic acid (PLGA) nanoparticles: Preparation, in vitro characterization and cyctotoxity 18(1) (pp. 1-11) https://doi.org/10.4314/tjpr.v18i1.1
  83. Öztürk et al. (2019) Clarithromycin-loaded poly (lactic-co-glycolic acid)(PLGA) nanoparticles for oral administration: effect of polymer molecular weight and surface modification with chitosan on formulation, nanoparticle characterization and antibacterial effects 11(10) https://doi.org/10.3390/polym11101632
  84. Ma et al. (2014) Homogeneous PLGA-lipid nanoparticle as a promising oral vaccine delivery system for ovalbumin 9(3) (pp. 129-136) https://doi.org/10.1016/j.ajps.2014.03.002
  85. Des Rieux, A.R., E.G.; Gullberg, E.; Preat, V.; Schneider, Y.J.; Artursson, P: Transport of nanoparticles across an in vitro model of the human intestinal follicle associated epithelium. Eur. J. Pharm. Sci.
  86. 25
  87. , 455–465 (2005).
  88. Ibrahim and Rosli (2020) Formulation, cellular uptake and cytotoxicity of thymoquinone-loaded PLGA nanoparticles in malignant melanoma cancer cells https://doi.org/10.2147/IJN.S269340
  89. Pishavar et al. (2019) Co-delivery of doxorubicin and TRAIL plasmid by modified PAMAM dendrimer in colon cancer cells, in vitro and in vivo evaluation 45(12) (pp. 1931-1939) https://doi.org/10.1080/03639045.2019.1680995
  90. Tiana et al. (2015) N-acetyl-d-glucosamine decorated polymeric nanoparticles for targeted delivery of doxorubicin: Synthesis, characterization and in vitro evaluation (pp. 246-254) https://doi.org/10.1016/j.colsurfb.2015.04.019
  91. Wei R, C.L., Zheng M, et al: Reduction-responsive disassemblable core-cross-linked micelles based on poly(ethylene glycol)-b-poly(
  92. N
  93. -2-hydroxypropyl methacrylamide)-lipoic acid conjugates for triggered intracellular anticancer drug release. Biomacromolecules.
  94. 13
  95. (8), 2429–2438 (2012).
  96. Wang CH, W.C., Hsiue GH: Polymeric micelles with a pH-responsive structure as intracellular drug carriers. JCR.
  97. 108
  98. (1), 140–149 (2005).
  99. L. Zhang, Z.C., H. Wang, S. Wu, K. Zhao, H. Sun, D. Kong, C. Wang, X. Leng and D. Zhu, : Preparation and evaluation of PCL-PEG-PCL polymeric nanoparticles for doxorubicin delivery against breast cancer. RSC. Adv. (2016).
  100. Hilgers et al. (1990) Caco-2 cell monolayers as a model for drug transport across the intestinal mucosa 7(9) (pp. 902-910) https://doi.org/10.1023/A:1015937605100
  101. Luo et al. (2017) Ascorbate-conjugated nanoparticles for promoted oral delivery of therapeutic drugs via sodium-dependent vitamin C transporter 1 (SVCT1) (pp. 1-11)
  102. Chehl N, C.G., Gong Q, Yeo CJ, Arafat HA: Anti-inflammatory effects of the Nigella sativa seed extract, thymoquinone, in pancreatic cancer cells. HPB (Oxford)
  103. 11
  104. (5), 373–381 (2009).
  105. Torres MP, P.M., Chakraborty S, Smith LM, Das S, Arafat HA, Batra SK.: Effects of thymoquinone in the expression of mucin 4 in pancreatic cancer cells: implications for the development of novel cancer therapies. Mol. Cancer. Ther.
  106. 9
  107. (5), 1419–1431 (2010).
  108. Woo CC, L.S., Gee V, et al. : Anticancer activity of thymoquinone in breast cancer cells: Possible involvement of PPAR g pathway. Biochem. Pharmacol.
  109. 82
  110. (5), 464–475 (2011).
  111. Paramasivam A, R.S., Vijayashree Priyadharsini J, Jayaraman G: Thymoquinone inhibits the migration of mouse neuroblastoma (Neuro-2a) cells by down-regulating MMP-2 and MMP-9. CJNM.
  112. 14
  113. (2), 0904–0912 (2016).